文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症新型临床表型的推导、验证及潜在治疗意义

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.
PubMed 文献 · JAMA · 2019-01-01
一句话结论回顾性分析识别出4种脓毒症临床表型(α、β、γ、δ),与宿主反应标志物和死亡率相关,模拟提示可能有助于理解治疗效应的异质性。

该研究对宾夕法尼亚州12家医院2010-2012年收治的20189例(16552例唯一患者)符合Sepsis-3标准的脓毒症患者进行回顾性分析,使用共识k均值聚类对29个变量推导表型。在第二数据库(2013-2014年,43086例患者,31160例唯一患者)、一项肺炎所致脓毒症前瞻性队列(n=583)和3项脓毒症随机对照试验(n=4737)中评估可重复性及与生物学参数和临床结局的相关性。识别出4种表型:α型最常见(33%),血管升压药使用最少;β型(27%)患者年龄较大,慢性病和肾功能不全较多;γ型(27%)炎症和肺功能障碍较多;δ型(13%)肝功能障碍和脓毒症休克较多。28天累积死亡率α型5%、β型13%、γ型24%、δ型40%,δ型在全部队列和试验中28天和365天死亡率最高(P < .001)。模拟模型显示,改变随机对照试验内表型频率可显著改变报告获益、伤害或无效应的比例。

要点

  • 在20189例脓毒症患者中识别出4种临床表型:α型33%、β型27%、γ型27%、δ型13%。
  • δ型表型肝功能障碍和脓毒症休克较多,28天死亡率40%,为4型中最高。
  • α型表型血管升压药使用最少,28天死亡率5%,为4型中最低。
  • 模拟提示改变随机对照试验内表型频率可改变治疗效应方向,如早期目标导向治疗从>33%可能获益变为>60%可能伤害。
  • 作者结论认为需进一步研究以确定这些表型在临床 care 和试验设计中的效用。

适用人群与场景

  • 推导队列:2010-2012年宾夕法尼亚州12家医院收治、入院6小时内符合Sepsis-3标准的脓毒症患者20189例(16552例唯一患者)。
  • 验证队列:2013-2014年第二数据库脓毒症患者43086例(31160例唯一患者),以及肺炎所致脓毒症前瞻性队列583例和3项脓毒症随机对照试验4737例。

诊断标准与关键阈值

  • Sepsis-3标准:入院6小时内符合Sepsis-3标准的脓毒症患者纳入推导队列。
  • 表型推导:对29个变量应用共识k均值聚类,识别出α、β、γ、δ四种表型。

研究设计与关键结果

  • 研究类型:回顾性分析,使用统计、机器学习和模拟工具;推导队列来自12家宾夕法尼亚州医院(2010-2012年),验证队列来自第二数据库(2013-2014年)、一项前瞻性队列(n=583)和3项随机对照试验(n=4737)。
  • 推导队列入群:20189例脓毒症患者,平均年龄64岁(SD 17),男性10022例(50%),平均24小时最大SOFA评分3.9(SD 2.4)。
  • 验证队列入群:43086例患者,平均年龄67岁(SD 17),男性21993例(51%),平均24小时最大SOFA评分3.6(SD 2.0)。
  • 表型分布:α型6625例(33%),β型5512例(27%),γ型5385例(27%),δ型2667例(13%);验证队列分布相似。
  • 28天累积死亡率:α型5691例唯一患者中287例死亡(5%);β型4420例中561例(13%);γ型4318例中1031例(24%);δ型2223例中897例(40%)。
  • 在所有队列和试验中,δ型表型28天和365天死亡率高于其他3种表型(P < .001)。
  • 模拟模型:改变随机对照试验内表型频率可显著改变报告获益、伤害或无效应的比例,例如早期目标导向治疗试验中表型频率变化可使结果从>33%可能获益变为>60%可能伤害。

证据类型、等级与局限

  • 证据类型:回顾性分析(数据来自多中心队列、前瞻性队列和随机对照试验的二次分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,这些表型与宿主反应模式和临床结局相关,模拟提示可能有助于理解治疗效应的异质性。
  • 作者结论认为,需进一步研究以确定这些表型在临床 care 中的效用以及用于指导试验设计和解读。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sepsis is a heterogeneous syndrome. Identification of distinct clinical phenotypes may allow more precise therapy and improve care.

OBJECTIVE: To derive sepsis phenotypes from clinical data, determine their reproducibility and correlation with host-response biomarkers and clinical outcomes, and assess the potential causal relationship with results from randomized clinical trials (RCTs).

DESIGN, SETTINGS, AND PARTICIPANTS: Retrospective analysis of data sets using statistical, machine learning, and simulation tools. Phenotypes were derived among 20 189 total patients (16 552 unique patients) who met Sepsis-3 criteria within 6 hours of hospital presentation at 12 Pennsylvania hospitals (2010-2012) using consensus k means clustering applied to 29 variables. Reproducibility and correlation with biological parameters and clinical outcomes were assessed in a second database (2013-2014; n = 43 086 total patients and n = 31 160 unique patients), in a prospective cohort study of sepsis due to pneumonia (n = 583), and in 3 sepsis RCTs (n = 4737).

EXPOSURES: All clinical and laboratory variables in the electronic health record.

MAIN OUTCOMES AND MEASURES: Derived phenotype (α, β, γ, and δ) frequency, host-response biomarkers, 28-day and 365-day mortality, and RCT simulation outputs.

RESULTS: The derivation cohort included 20 189 patients with sepsis (mean age, 64 [SD, 17] years; 10 022 [50%] male; mean maximum 24-hour Sequential Organ Failure Assessment [SOFA] score, 3.9 [SD, 2.4]). The validation cohort included 43 086 patients (mean age, 67 [SD, 17] years; 21 993 [51%] male; mean maximum 24-hour SOFA score, 3.6 [SD, 2.0]). Of the 4 derived phenotypes, the α phenotype was the most common (n = 6625; 33%) and included patients with the lowest administration of a vasopressor; in the β phenotype (n = 5512; 27%), patients were older and had more chronic illness and renal dysfunction; in the γ phenotype (n = 5385; 27%), patients had more inflammation and pulmonary dysfunction; and in the δ phenotype (n = 2667; 13%), patients had more liver dysfunction and septic shock. Phenotype distributions were similar in the validation cohort. There were consistent differences in biomarker patterns by phenotype. In the derivation cohort, cumulative 28-day mortality was 287 deaths of 5691 unique patients (5%) for the α phenotype; 561 of 4420 (13%) for the β phenotype; 1031 of 4318 (24%) for the γ phenotype; and 897 of 2223 (40%) for the δ phenotype. Across all cohorts and trials, 28-day and 365-day mortality were highest among the δ phenotype vs the other 3 phenotypes (P < .001). In simulation models, the proportion of RCTs reporting benefit, harm, or no effect changed considerably (eg, varying the phenotype frequencies within an RCT of early goal-directed therapy changed the results from >33% chance of benefit to >60% chance of harm).

CONCLUSIONS AND RELEVANCE: In this retrospective analysis of data sets from patients with sepsis, 4 clinical phenotypes were identified that correlated with host-response patterns and clinical outcomes, and simulations suggested these phenotypes may help in understanding heterogeneity of treatment effects. Further research is needed to determine the utility of these phenotypes in clinical care and for informing trial design and interpretation.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Seymour CW, Kennedy JN, Wang S, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019. PMID: 31104070. doi:10.1001/jama.2019.5791

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。